Prevention and Management of Injection Site Reactions in Type 2 Inflammation-Targeted Biologic Therapies for Atopic...

INTRODUCTION: Biologic therapies targeting the type 2 inflammatory pathway have transformed the management of moderate-to-severe atopic dermatitis (AD). Injection site reactions (ISRs) are the most common localized adverse events associated with these agents and might influence treatment persistence. OBJECTIVE: To present a practical, evidence-informed clinical framework for the prevention and management of ISRs associated with type 2 biologic therapies used in the treatment of AD. METHODS: A narrative review of ISR incidence reported in pivotal phase 3 trials was integrated with real-world observational evidence and contemporary prescribing trends within advanced practice clinician (APC)-integrated dermatologic practice. RESULTS: Across pivotal trials of type 2 pathway biologics, ISR incidence has ranged from approximately 4% to 19%, depending on mechanism of action and comparator arm. Interleukin (IL)-4/IL-13 pathway inhibition has demonstrated ISR rates of approximately 10% to 18%, compared with 6% to 10% in placebo arms. Selective IL-13 inhibitors have shown ISR rates ranging from 4% to 14%, while IL-31 receptor blockade trials have reported localized reactions in approximately 8% to 15% of participants. Real-world observational and meta-analytic data confirm that most ISRs are mild to moderate in severity and rarely lead to treatment discontinuation, with discontinuation rates generally reported between 1% and 2%. DISCUSSION: Although numerically common, ISRs are typically benign, self-limited, and manageable with appropriate counseling and supportive care. Variability in reported incidence likely reflects differences in molecular structure, formulation characteristics, delivery devices, and trial methodology rather than meaningful differences in systemic safety. Structured anticipatory guidance and standardized management pathways might reduce anxiety-driven discontinuation and improve treatment persistence. CONCLUSION: Proactive counseling, optimization of injection technique, and symptom-directed management strategies can reduce morbidity associated with ISRs and support long-term adherence in dermatologist-directed, APC-integrated practice models.